When was 89bio founded?

89bio was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is 89bio located?

89bio is headquartered in San Francisco, United States. It is registered at 142 Sansome St 2nd Floor, San Francisco, CA 94104.

How many employees does 89bio have?

As of Apr 30, 2026, the latest employee count at 89bio is 126.

Is 89bio a funded company?

89bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Oct 25, 2018.

How much is 89bio worth?

The last known valuation of 89bio was $***** as of Sep 17, 2025.

When was the latest funding round of 89bio?

89bio's latest funding was a $***** Series A round on Oct 25, 2018, with participation from 4 investors. Its primary sector is Metabolic Diseases. In United States, the Metabolic Diseases sector has seen $761M in funding in 2026 to date.

Where does 89bio rank among its competitors?

89bio ranks 4th amongst 42 active competitors, of which 10 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Sernova, which secured $345K in Oct, 2025.

Who are the top competitors of 89bio?

89bio's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Among them, Sernova secured the most recent funding round in October, 2025.

89bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is 89bio an acquired company?

89bio got acquired by Roche on Sep 17, 2025.

Company Details

89bio is developing therapies for treating nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. The lead candidate is BIO89-100, which is a long-acting glycopegylated fibroblast growth factor 21 analog used for treating NASH. They have developed the product from their proprietary glycopegylation technology. The candidate is in phase I clinical trial.

Website: 89bio.com
Email ID: *****@89bio.com
Registered Address: 142 Sansome St 2nd Floor, San Francisco, CA 94104

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Acquired

Total Funding

$60M in 1 round

Latest Funding Round

Series A, Oct 25, 2018, $*****

Last Known Valuation

$***** as on Sep 17, 2025

Investors

Orbimed & 4 more

Ranked

4^th among 42 active competitors

Employee Count

126 as on Apr 30, 2026

Similar Companies

Rhythm Pharmaceuticals & 58 more

Exit Details

Acquired by Roche (Sep 17, 2025)

View 89bio's full profile

89bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
89bio, Inc. CIN: 1785173 , United States, Active	Jun 27, 2019	-	-	-
89BIO, INC CIN: 7491937 , United States, Active	Jul 01, 2018	-	70 (As on Dec 31, 2023)	-

89bio got acquired by Roche on Sep 17, 2025 at an acquisition amount of $*****.

Click here to take a look at 89bio's acquisition in detail

89bio has raised a total funding of $60M over 1 round. Its latest funding round was a Series A round on Oct 25, 2018 for $*****. 4 investors participated in its latest round. 89bio has 5 institutional investors.

Here is the list of recent funding rounds of 89bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 25, 2018	4413676	Series A	9611491	3967109	2721580	4839533

Access funding benchmarks and valuations. Sign up today!

View details of 89bio's funding rounds and investors

89bio's employee count trend

89bio has 126 employees as of Apr 26. Here is 89bio's employee count trend over the years:

Uncover 89bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 89bio include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Here is the list of Top 10 competitors of 89bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	70/100
3rd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, Sutter Hill Ventures ... & 7 others	68/100
4th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	RA Capital Management, Orbimed & 3 others	64/100
5th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Evotec & 1 others	62/100
6th	Genfit 1999, Loos (France), Public	Therapeutics for cardiometabolic and neurodegenerative diseases.	-	Eiffel Investment Group, Ridgeback Capital Management ... & 2 others	59/100
7th	OptiBiotix Health 2012, York (United Kingdom), Public	Developer of microbial strains for the treatment of human metabolic diseases	-	Seneca EIS Portfolio Fund, Enterprise Ventures ... & 2 others	55/100
8th	NGM Biopharmaceuticals 2007, San Francisco (United States), Public	Developer of biologics for the treatment of cardio-metabolic and liver disease	$359M	The Column Group, Prospect Venture Partners ... & 7 others	55/100
9th	PhaseBio Pharmaceuticals 2002, Malvern (United States), Public	Developer of novel drugs to treat metabolic and cardiopulmonary disorders	$152M	Johnson & Johnson Innovation, Astellas Venture Management ... & 12 others	50/100
10th	Metacrine 2015, San Diego (United States), Public	Developer of protein sensitizers for insulin in type 2 diabetes and modulators for metabolic diseases	$125M	VenBio, Venrock & 15 others	49/100